of Tc-DB8

Phase 2Small molecule

TTomsk National Research Medical Center of the Russian Academy of Sciences

of Tc-DB8 is one of 2 small molecule programs targeting Primary Breast Cancer. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Primary Breast CancerEnrolling by invitation

Primary Breast CancerPhase 2

Enrolling by invitation

Competition

Competitive Landscape

2 competitors in Primary Breast Cancer

#DrugCompanyPhaseTrials

SHR-A1811

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 3

1 2

of Tc-DB8

TTomsk National Research Medical Center of the Russian Academy of Sciences

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Prostate Cancer1 trial

SPECT Imaging of Gastrin Releasing Peptide Receptors Using Labeled Technetium-99m DB8 ([99mTc]Tc- DB8) in Prostate Cancer and Breast Cancer Patients

Completed·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 1·NCT05940298·10 enrolled

Primary Breast Cancer1 trial

SPECT/CT Imaging of Different Types of HER2 Expression in Breast Cancer Using Technetium-99m-labelled Affibody [99mTc]Tc -ZHER2:4107

Enrolling by invitation·TTomsk National Research Medical Center of the Russian Academy of Sciences·Phase 2·NCT07292571·50 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for of Tc-DB8. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — of Tc-DB8 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for of Tc-DB8. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Tomsk National Research Medical Center of the Russian Academy of Sciences company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: TTomsk National Research Medical Center of the Russian Academy of Sciences

of Tc-DB8

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Prostate Cancer1 trial

Primary Breast Cancer1 trial

References

Drug Info

Quick Facts

Related News